GILD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Gilead Sciences is a good buy right now for a beginner-focused long-term investor with $50,000-$100,000 available. The stock has supportive long-term fundamentals, recent positive pipeline and regulatory catalysts, and a generally constructive Wall Street stance. The current pre-market dip to around 135.2 looks like an acceptable entry rather than a reason to wait, especially since the stock is trading near bullish technical levels and analyst sentiment has improved.
GILD is in a bullish technical trend. MACD histogram is positive and expanding, the moving averages are aligned bullishly (SMA_5 > SMA_20 > SMA_200), and price is trading above the pivot at 132.317. Pre-market price at 135.2 is just below R1 at 135.438 and near R2 at 137.366, which suggests momentum remains intact. RSI_6 at 72.815 is elevated but not signaling a clear reversal here. Overall, the chart supports a positive trend with near-term strength.
Recent catalysts are clearly positive: FDA accelerated approval for Hepcludex in chronic hepatitis delta virus infection, completion of the Tubulis acquisition to strengthen oncology, and continued momentum in the HIV franchise including Yeztugo. News flow is favorable and suggests both near-term commercial tailwinds and longer-term pipeline value.
The main negatives are that the stock is not cheap relative to peers, some analysts remain more conservative on the longer-term potential of Yeztugo and Trodelvy, and Congress trading data shows one recent sale with no purchases, which is a mild cautionary signal. The pre-market price is also slightly soft on the day.
No usable latest-quarter financial statement data was provided because the financial snapshot returned an error. However, analyst commentary on the latest quarter was positive: Truist noted Q1 top- and bottom-line beats with raised FY26 revenue guidance, driven by HIV strength and Yeztugo. That indicates the latest quarter season was strong and growth trends are improving.
Analyst sentiment has turned more positive recently. Maxim upgraded GILD to Buy with a $165 target, Jefferies initiated Buy with a $180 target, Truist keeps Buy with a $157 target, Citi keeps Buy with a $165 target, and Morgan Stanley remains Overweight with a $168-$175 target range. RBC is the main more cautious voice with Sector Perform and a $122 target. Overall, Wall Street leans bullish, with the pros citing durable HIV dominance, improving base-business growth, and pipeline upside, while the main con is that some long-term assets are still viewed as early or not yet fully valued.
